Non-Myeloablative (NMA) Allogeneic Hematopoietic Stem Cell Transplant for the Treatment of Patients with Hematologic Malignancies Using Busulfan, Fludarabine and Total Body Irradiation (Bu/Flu/TBI) Conditioining: Results of a Phase II Trial

Non-myeloablative (NMA) allogeneic transplant for the treatment of hematologic malignancies has become the standard of care for patients unable to tolerate myeloablative conditioning. The BuFluTBI transplant regimen was designed with the primary goal of reducing non-relapse mortality (NRM) while maximizing primary disease control in older and infirm patients.